LGND Ligand Pharmaceuticals Incorporated

NASDAQ
$301.52

Ligand Pharmaceuticals Incorporated (LGND) is expected to report earnings on November 6, 2026, before the market open. The consensus earnings estimate is $1.42 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.5% since its last earnings release on August 6, 2026.

Ligand Pharmaceuticals Beat Expectations, Narrows Earnings Guidance Above Estimates
Thursday, August 6, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 6
Friday · 7:00 AM ET
Earnings Whisper
-
vs $1.42 (GAAP)
Rev est $77.37M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $288.36

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Inc is a biopharmaceutical company with a business model that is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Held By 8 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.